DNA therapeutics

With new spinoff, biotech goes all-in on DNA sales

By GREGORY ZELLER // A Stony Brook biotech with a growing international reputation for supply-chain security has spun off a new company focused on DNA modification and production. Stony Brook-based Applied DNA Sciences on Tuesday announced the formation of LineaRx Inc., a wholly owned subsidiary that will concentrate on commercializing the parent company’s extensive experience in the design, manufacture and chemical modification of DNA by large-scale polymerase chain reaction – big news for scientists working…


As biopharma blossoms, ace DNA producer locks in

By GREGORY ZELLER // Applied DNA Sciences has long proclaimed textiles – your cotton shirt, your leather shoes and the industries that produce them – as its primary vertical market, the ideal sector in which to apply its patented DNA-based security and authentication protocols. But a wholly different use for its coveted DNA supplies may soon eclipse textile-tracking as the Stony Brook biotech’s primary moneymaker. That’s the word from President and CEO James Hayward, who…